Atlanta, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, announced today it has signed a contract with a partner for the use of RevID at a 350-bed medical center based in California. Through its automated charge reconciliation, RevID will contribute to improved revenue integrity and financial performance.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation ensures that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“Our partners are entrusted with helping their clients improve operational and financial results, and we appreciate their faith in RevID’s ability to optimize charge capture at this medical center,” said Ben Stilwill, President, Streamline Health. “We look forward to accelerating the adoption of our unique, innovative solutions through our partners to help our nation’s healthcare providers receive accurate payment for the services they offer.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Media
David Kosloski
Vice President, Marketing & Communications
651.308.1395
dThis email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.59 |
| Daily Change: | -0.02 -0.55 |
| Daily Volume: | 8,872 |
| Market Cap: | US$15.330M |
December 18, 2024 December 16, 2024 October 08, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
